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outcome of a cost-effectiveness analysis. This impact is most
acute when the members of a large population can mix freely
(there is little compartmentalisation), for example across
different age groups, there is signiﬁcant transmission (the mean
number of secondary infections generated by each primary infec-
tion is greater than one) and where transmission is rapid (short
incubation period). This ﬁnal condition is important if the cost-
effectiveness analysis has a short time horizon, particularly where
costs are accumulated sooner than beneﬁts (as in a vaccination
program). This has been demonstrated in the analysis of both
varicella zoster and hepatitis B virus vaccination programs. The
circumstances in which transmission modelling is of greatest
value will be further discussed, as too will those in which an
individual based analysis sufﬁces.
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OBJECTIVES: The project AIDA (Atlas of Italian Administra-
tive Database) recently shown that collection of administrative
data in Italy is widespread both at national and local level; Aim
of this study is to evaluate the use of these databases in health
economics ﬁeld in Italy focusing on Friuli Venezia Giulia (FVG)
Region as pilot. METHODS: A Pubmed search was carried out
using 11 different key words to match studies based on admin-
istrative data collected on FVG population published till
December 2006. The articles included in the analysis were then
classiﬁed according to therapeutic area, period, data source,
population, other data. RESULTS: Initially our search identiﬁed
123 articles, but only 24 were eligible for inclusion in our
project. 7 studies were focused on drugs efﬁcacy and related
AEs, 8 studies estimated prevalence, incidence or risk factor of
some major diseases such as cancer, coronary or ischemic
disease; 6 studies evaluated the effectiveness of surveillance
campaigns and 2 studies were focused on quality of care pro-
vided by Regional Healthcare System. The articles were all pub-
lished in the period between 1990 and 2006, and 58% were
published in the last 7 year. All the studies included in the
analysis gave information about resources use and consumption
but only one study appraised the direct cost. Hospital discharge
records, prescriptions registries and disease registries were most
commonly used database in the eligible studies. CONCLU-
SION: FVG Healthcare Informative System is one of the best
developed and with the highest quality of data collection at a
local level in Italy, for this reason we have chosen it as pilot;
our search showed that in recent years use of administrative
data as proxy outcome and cost estimation was implemented
compared to years ’90 but they remain still underused in
Health Technology Assessment.
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OBJECTIVES: This study presents a methodology to estimate
prevalence rates for speciﬁc diagnosed conditions among
the ~170 million Americans covered by employer-sponsored
insurance (ESI). Individuals with ESI represent over 58% of the
U.S. population, a large group with fewer cost barriers to care.
METHODS: Estimates were made from the 2005 MarketScan®
databases, which include all health care claims for approximately
20 million employees, dependents, and retirees with ESI. The
Sample Select Prevalence tool identiﬁed patients diagnosed with
asthma, osteoporosis, allergic rhinitis (AR), essential hyperten-
sion, rheumatoid arthritis (RA), type II diabetes, congestive
heart failure (CHF), or hypercholesterolemia (using relevant
ICD-9-CM diagnosis codes), and calculated prevalence rates.
Weights were developed based on the Medical Expenditure
Panel Survey (MEPS), a probability sample that estimates the
number of Americans by health insurance type. The ratio of
MEPS population estimate to MarketScan population within
certain strata of demographic characteristics provided the pro-
jection weights. Prevalence rates were calculated for the total
population and by age, gender, geographic region, and health
plan type. RESULTS: Based on the 2005 MarketScan data-
bases, annual rates per 100,000 were as follows: 11,175.69
(hypertension), 4,813.54 (type II diabetes), 4,739.46 (AR),
4,275.79 (hypercholesterolemia), 3,164.33 (asthma), 962.80
(osteoporosis), 736.29 (CHF), 521.59 (RA). These rates varied
by age, gender, and geography. Annual expenditures per patient
ranged from $5,788 (AR) to $37,105 (CHF). CONCLUSION:
Reliable estimates of prevalence and costs for diagnosed health
conditions are valuable to policy makers, providers, and payers.
This study demonstrates a reliable projection methodology for
estimating annual prevalence, treatment events, and costs asso-
ciated with a diagnosed disease or condition based on a large
convenience sample of health care claims data.
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OBJECTIVES: The Expected Value of Perfect Parameter Infor-
mation (EVPPI) requires three level simulation in non-linear
micro-simulation models, which is time consuming. Meta-
modelling approaches reduce the time needed to evaluate the
inﬂuence of uncertainty in complex health economic models.
Here, two meta-modelling approaches are compared: spatial
interpolation (SI) and ordinary least squares (OLS).
METHODS: Both methods are applied to a drug-drug com-
parison in a micro-simulation schizophrenia model. The Net
Beneﬁts appear to depend rather non linearly on the underlying
variables as assessed using the R2 and the RESET-test. Ordi-
nary least squares is applied using 950 model runs. SI is applied
using 100 and 950 model runs. Subsequently both meta-
modelling methods are used to predict 50 out-of-sample runs
and evaluated with the Root Mean Squared Prediction Error
(RMSPE) and the time needed to estimate the EVPPI.
RESULTS: One run of the micro-simulation model takes 11
minutes. The SI 950 is more accurate than the OLS and SI 100,
which are comparable (average RMSPE for net beneﬁts for two
treatments 3006, 4842, and 4823 respectively). The SI 950
EVPPI calculation takes much longer time to complete the cal-
culations; the SI 100 on the other hand is much quicker than
the OLS (11005 minutes for the OLS and 2672 minutes for the
SI 100). CONCLUSION: The SI is a frequentistic approach
with great resemblance with the Bayesian Gaussian Process
meta-modeling method. If a simulation model takes very long
to come up with results or the model is non-linear, SI is the
superior meta-modelling technique. If the model is linear, SI is
fancy but not ideal.
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